A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Launched by JANSSEN RESEARCH & DEVELOPMENT, LLC · Oct 9, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the long-term safety and tolerability of a treatment called JNJ-81201887 for people with Geographic Atrophy (GA), a condition related to Age-related Macular Degeneration (AMD) that affects vision. Participants in this study will have previously received treatment with JNJ-81201887 or a placebo (a fake treatment) in earlier studies. The trial is open to adults aged 21 and older, and both men and women can participate without any specific contraception requirements.

If you decide to join the study, you will receive an injection of the medication directly into your eye, which is a common procedure for eye treatments. Participants will be monitored over time to see how well they tolerate the treatment and to check for any potential side effects. It’s important to understand that you’ll need to sign a consent form to confirm that you understand what the study involves and agree to participate. There are no specific exclusion criteria, making it more accessible for those who qualify.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants who were enrolled and received treatment with JNJ-81201887 or sham in a parent clinical study (81201887MDG2001, 81201887MDG1003)
• • Females (women of childbearing potential), male participants, and partners of male participants will not be required to use contraception in this LTE study
• • Must sign an informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study. The ICF may be signed by an impartial witness and/or legally designated representative depending on national/local regulations
• Exclusion Criteria:
• • There are no exclusion criteria for this LTE study